BSBin Shang

Bin Shang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bin Shang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Shujuan Jiang

    Department of Pulmonary and Critical Care Medicine, Shandong Provincial Hospital, Shandong University, China

    3 shared publications
  • Bin Liang

    Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China

    1 shared publication
  • Chunyan Xing

    Department of Pulmonary and Critical Care Medicine, Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan, China

    1 shared publication
  • Daowei Li

    Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital, China

    1 shared publication
  • Gang Chen

    Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China

    1 shared publication
  • Hancheng Wu

    Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China

    1 shared publication

Latest Publications

  • Open Access

    Identification and validation of parthanatos-related genes in lung adenocarcinoma and construction of a prognostic risk model

    by Yanna Yang, Jie Liu, Bin Shang, Shujuan Jiang

    Background: As a major cause of cancer-related death, lung adenocarcinoma (LUAD) remains a significant health challenge. Parthanatos plays a crucial role in tumor progression, influencing cancer cell survival and therapy resistance. This study constructed a parthanatos-based prognostic model and explored its associated biological processes. Methods: Data on LUAD transcriptomics and parthanatos-related genes were collected from publicly databases and related literature. Differential expression analysis and weighted gene co-expression network analysis were employed to identify candidate genes. Univariate Cox regression analysis and machine learning algorithms were employed to screen prognostic genes and construct the risk model. Gene expression patterns and intercellular communication within distinct cell types were explored by single-cell sequencing. Lastly, prognostic gene expression in tissue samples was verified by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and western blotting. Results: PPP1R14B , MIF , ALG3 , C11orf24 , and MZT2A were identified as prognostic genes. The risk model had good predictive performance. The risk score effectively stratified patients into high- and low-risk groups with significantly divergent overall survival (p< 0.0001). Prognostic genes were involved in vital processes such as DNA replication, protein metabolism, and immune response. Single-cell analysis highlighted expression variations across cell types, particularly in epithelial cells, with strong communication from myeloid cells and fibroblasts. RT-qPCR confirmed the high expression of prognostic genes in LUAD. Importantly, PPP1R14B expression was particularly significant, and it potentially influenced the LUAD malignant phenotype. Conclusion: This study constructed and validated a risk model for LUAD associated with parthanatos, providing new insights into the pathological mechanisms of LUAD and highlighting potential therapeutic targets.

  • Open Access

    FXR shapes an immunosuppressive microenvironment in PD-L1lo/– non-small cell lung cancer by upregulating HVEM

    by Xiaolong Xu, Bin Shang, Hancheng Wu, Xiuye Jin, Junren Wang, Jing Li, Daowei Li, Bin Liang, Xingguang Wang, Lili Su, et al.

    Immune checkpoint therapy has changed cancer treatment, including non-small cell lung cancer (NSCLC). The unresponsiveness of PD-L1 lo/– tumors to anti–PD-1/PD-L1 immunotherapy is attributed to alternative immune evasion mechanisms that remain elusive. We previously reported that farnesoid X receptor (FXR) was increased in PD-L1 lo/– NSCLC. Herein, we found that immune checkpoint HVEM was positively correlated with FXR but inversely correlated with PD-L1 in NSCLC. HVEM was highly expressed in FXR hi PD-L1 lo NSCLC. Consistently, clinically relevant FXR antagonist dose-dependently inhibited HVEM expression in NSCLC. FXR inhibited cytokine production and cytotoxicity of cocultured CD8 + T cells in vitro, and it shaped an immunosuppressive tumor microenvironment (TME) in mouse tumors in vivo through the HVEM/BTLA pathway. Clinical investigations show that the FXR/HVEM axis was associated with immunoevasive TME and inferior survival outcomes in patients with NSCLC. Mechanistically, FXR upregulated HVEM via transcriptional activation, intracellular Akt, Erk1/2 and STAT3 signals, and G1/S cycle progression in NSCLC cells. In vivo treatment experiments demonstrated that anti-BTLA immunotherapy reinvigorated antitumor immunity in TME, resulting in enhanced tumor inhibition and survival improvement in FXR hi PD-L1 lo mouse Lewis lung carcinomas. In summary, our findings establish the FXR/HVEM axis as an immune evasion mechanism in PD-L1 lo/– NSCLC, providing translational implications for future immunotherapy in this subgroup of patients.


  • Clinical Characteristics and Economic Burden of Asthma in China: A Multicenter Retrospective Study

    by Bin Shang, Xiangguo Li, Yu Xu, Wenxin Ren, Junren Wang, Chunyan Xing, Shujuan Jiang, Jian Sun

    Asthma is a common chronic airway inflammation that produces a healthcare burden on the economy. We aim to obtain a better understanding of the clinical status and disease burden of patients with asthma in China. A retrospective study was carried out based on the computerized medical records in the Jinan Health Medical Big Data Platform between 2011 and 2019 (available data from 38 hospitals). The asthma severity of each patient was assessed retrospectively and categorized as mild, moderate, or severe according to Global Initiative for Asthma 2020 (GINA 2020). The results revealed that the majority (75.0%) of patients suffered from mild asthma. Patients treated with inhaled corticosteroids (ICS)/long-acting beta-agonists (LABA) at emergency department visits had lower frequencies of exacerbations compared with non-ICS/LABA-treated patients. The incidence rates for 1, 2, 3, and 4 exacerbation of the patients treated with ICS/LABA are lower than those treated without ICS/LABA (14.49 vs. 15.01%, 11.94% vs. 19.12%, 6.51% vs. 12.92% and 4.10% vs. 9.35%). The difference got a statistical significance Chronic obstructive pulmonary disease (COPD) and gastroesophageal reflux disease (GERD), two comorbidities related to asthma, were risk factors for asthma exacerbation. Finally, patients who suffered from exacerbations produced a heavier economic burden compared to the patients who never suffered exacerbations (mean costs are ¥3,339.67 vs. ¥968.45 separately). These results provide a reference for clinicians and patients to obtain a better treatment and therapy strategy management for people living with asthma.


  • Open Access

    Ku80 correlates with neoadjuvant chemotherapy resistance in human lung adenocarcinoma, but reduces cisplatin/pemetrexed-induced apoptosis in A549 cells

    by Bin Shang, Yang Jia, Gang Chen, Zhou Wang

    Ku80 is a DNA repair protein which involves in cell apoptosis and chemoresistance. However, it is unclear whether Ku80 correlates with the efficiency of neoadjuvant chemotherapy in human lung adenocarcinoma, and modulates cisplatin/pemetrexed-induced lung cancer cell apoptosis in vitro. We recruited 110 patients with stage IIIA lung adenocarcinoma, who received 2 cycles of neoadjuvant chemotherapy, and their lungs were reevaluated by CT scan. Immunohistochemistry and qRT-PCR was performed to detect the expression level of Ku80. A549 cells were transfected by lentiviral vector containing shRNA and full length cDNA to knockdown or upregulate Ku80 gene expression. CCK8 assay, flow cytometry and Western blot were employed to determine the viability and apoptosis of A549 cells treated with cisplatin combined with pemetrexed. Ku80 expression was detected in 76 patients (69%). There were 38 patients who responded to chemotherapy, where Ku80 was positively expressed in 7 cases (18.4%). Immunohistochemical score of Ku80 protein in the response group (2.079 ± 1.617) to chemotherapy was lower than that in the nonresponse group (5.597 ± 2.114, P < 0.05). Tissue samples from the nonresponse group exhibited higher Ku80 mRNA levels compared to the response group. Ku80 knockdown by shRNA augmented cisplatin/pemetrexed-induced decline in viability, whereas Ku80 overexpression attenuated viability reduction induced by these drugs compared to control A549 cells. Both flow cytometry and Western blot analysis displayed that the apoptotic rate of Ku80 shRNA-transfected A549 cells was significantly increased compared to control cells treated with cisplatin/pemetrexed, which was lowered by Ku80 overexpression. Ku80 could predict the probability of resistance to neoadjuvant chemotherapy in lung adenocarcinoma, and reduced cisplatin and pemetrexed-induced apoptosis in A549 cells.